New PET Tracer Shows Promise for uPAR-Targeted Therapy of Neuroendocrine Neoplasms miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Baltimore (PRWEB) June 22, 2022 (Baltimore, MD) David A. Riseberg, M.D., Chief of Medical Oncology and Hematology at Mercy Medical Center in Baltimore,
E-Mail
IMAGE: Representative examples of lesions in the same patients scanned at 1h p.i. and 3h p.i. From left to right: CT, 64Cu-DOTATATE PET, fused 64Cu-DOTATATE PET/CT and maximum intensity projection (MIP). view more
Credit: Images created by M. Loft et al., ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark.
Reston, Virginia The imaging time window of 64Cu-DOTATATE positron emission tomography/computed tomography (PET/CT) for patients with neuroendocrine neoplasms can be expanded from one hour to three hours post-injection, according to new research published in the January issue of the
Journal of Nuclear Medicine. In a head-to-head comparison of scans performed at the two time intervals, there were no significant differences in the number of lesions detected, and tumor-to-normal tissue ratios remained high in all key organs.